Quantitative expression of MMP-2 and FN in high metastatic and low metastatic cell lines of breast cancer

To analyze the relation of matrix metalloproteinase-2(MMP-2) and Fibronection (FN) mRNA expression with metastasis of breast cancer and elucidate the role of MMP-2 and FN in breast cancer metastasis.Methods The expression of MMP-2 and FN mRNA in breast cancer cell lines was detected by fluorescence-quantitative RT-PCR.The expression of MMP-2 and FN protein was detected by Western blots.Results The expression of MMP-2 and FN mRNA was down-regulated in high metastatic cell lines MDA-MB-231,MDA-MB-435,but up-regulated in low metastatic cell lines MDA-453,T47D,SK-BR-3 and non-metastatic cell line MCF-7,ZR-75-30.The protein expression of MMP-2 and FN was up-regulated in high mestastic cell lines,and down-regulated in low metastatic cell lines.Conclusion The mRNA and protein expression of MMP-2 and FN was related with breast cancer metastasis.The mRNA expression of MMP-2 and FN is feed-back regulated with protein expression.6 refs,4 figs,2 tabs.

Study on the high risk factors related to different metastatic sites of advanced breast cancer

Objective:Several studies indicated that many factors have relationship with the metastatic sites of advanced breast cancer.This retrospective study investigated the high risk factors which related to the different metastatic sites of stage IV breast cancer.Patients and methods:From January 2003 to December 2005 a total of 387 consecutive breast cancer patients were retrospectively analyzed.The relationships between different categorical variables and breast cancer were identified by Chi-square tests.Results:The high risk factors of metastatic breast cancer included the overexpression of HER-2 and lymph nodes invasion.The overexpression of HER-2 and lymph nodes invasion had a significantly difference between metastatic breast cancer and breast cancer without metastasis(P=0.018,P<0.001,respectively).As for metastatic breast cancer patients with only one single metastatic organ,the overexpression of HER-2 had a significantly high positive rate in patients with visceral metastases when compared with bone metastasis(P=0.045).Conclusion:The overexpression of HER-2 and lymph nodes invasion significantly influenced the metastasis of breast cancer.Overexpression of Her-2 was high risk factors for breast cancer developed to visceral metastases disease.

Chidamide Combined with Paclitaxel Liposome for the Treatment of Advanced HER2-negative Breast Cancer in Clinical Study

The purpose of this study was to investigate the efficacy and safety of chidamide combined with paclitaxel liposome in the treatment of advanced HER-2-negative breast cancer.First,41 patients with advanced HER-2-negative breast cancer who had received two chemotherapy regimens from May 2017 to November 2017 were randomly selected to receive chidamide combined with paclitaxel liposome treatment(observation group,n=20)or placebo combined with paclitaxel liposome treatment(control group,n=21).The treatment scheme of the observation group was oral chidamide 30mg twice a week for 2 months.In addition,on day 1,the patients were given paclitaxel liposome orally and intravenously administered with 175 mg/m2 for 1 cycle for 21 days and 3 cycles of chemotherapy.The treatment scheme of the control group was oral placebo 30 mg twice a week for 2 months.In addition,the method of paclitaxel liposome administration was the same as the observation group.The response rate(RR),disease control rate(DCR),and progression-free survival(PFS)were compared between the two groups.The results showed that all the 41 patients could be evaluated.In the observation group,CR5,PR7,SD5 and PD3 were obtained.RR was 60.0%and DCR was 85.0%.In the control group,CR3,PR3,SD5 and PD10 were obtained.RR was 28.6%and DCR was 52.4%.RR and DCR in the observation group were better than those in the control group,and the difference was statistically significant(P<0.05).The median PFS of the observation group was 5.2 months,longer than that of the control group(3.1 months,P<0.05).The main adverse reactions in the two groups were gastrointestinal reactions and bone marrow suppression,with grade 1~2 as the main ones.The incidence of leukopenia,thrombocytopenia and nausea and vomiting in the observation group was higher than that in the control group(P<0.05).Therefore,the chidamide combined with paclitaxel liposome is effective in the treatment of advanced HER-2-negative breast cancer,and the adverse reactions can be tolerated.

乳腺癌原发灶与转移灶内ER、PR、Her-2表达的差异及其对治疗的影响

目的:探索ER、PR、Her-2在乳腺癌原发灶及转移灶内表达的差异,及其对治疗的影响。方法:用IHC方法对44例有淋巴结或者远处转移灶或者局部复发的乳腺癌患者原发灶及转移灶标本配对进行ER、PR、Her-2检测,然后分别计算二者表型的表达率以及变化率,并根据原发灶及转移灶ER、PR、Her-2表达的情况调整治疗方案用于临床治疗。结果:44例乳腺癌组织的ER、PR、Her-2在原发灶的阳性表达率分别为68.2%、61.4%、18.2%,而在转移灶中的阳性表达率分别为65.9%、63.6%、9.1%,三者在原发灶及转移灶中的阳性表达率差异均无显著统计学意义。ER、PR、Her-2在原发灶与转移灶间的总变化率分别为:25.0%(11例)、27.3%(12例)、9.1%(4例)。44例乳腺癌患者中,内分泌治疗增加12例,占比27.3%。结论:由于ER、PR、Her-2在乳腺癌原发灶与转移灶间的表达存在一定的差异,因此,对复发转移灶的受体再检查是必要的,并根据原发灶及转移灶的受体表达情况综合考虑治疗方案。

曲妥珠单抗及多西他赛联合护理干预治疗转移性乳腺癌HER-2强表达患者75例

目的探讨转移性乳腺癌HER-2强表达患者采用曲妥珠单抗及多西他赛治疗联合护理的临床效果。方法将2011年3月至2014年5月收治的150例转移性乳腺癌HER-2强表达患者按随机数字表法分为研究组和对照组,各75例。对照组患者仅使用曲妥珠单抗及多西他赛药物治疗,研究组患者在对照组基础上联合护理干预措施。结果研究组患者接受3个月的治疗后发热、皮疹、骨髓抑制、胃肠道不适等不良反应发生率均低于对照组(χ2=7.2921,P=0.006 9<0.05);两组患者治疗3个月后的卡氏生活质量评分(KPS)和生活质量评定量表评分(QOL)显著高于治疗前(P<0.05),且研究组评分显著高于对照组(P<0.05);治疗3个月后,研究组患者的病情稳定、疾病进展发生率分别为6.67%和2.66%,均低于对照组患者的2.66%和18.67%(χ2=10.074 6,P=0.001 5<0.05)。结论转移性乳腺癌HER-2强表达患者在采用曲妥珠单抗及多西他赛治疗基础上联合护理干预措施疗效更显著,可降低不良反应发生率,改善生活质量,促进机体康复,值得临床推广。